Cargando…

Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness

After two years since the declaration of COVID-19 as a pandemic by the World Health Organization (WHO), more than six million deaths have occurred due to SARS-CoV-2, leading to an unprecedented disruption of the global economy. Fortunately, within a year, a wide range of vaccines, including pathogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chattopadhyay, Anirudha, Jailani, A. Abdul Kader, Mandal, Bikash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458178/
https://www.ncbi.nlm.nih.gov/pubmed/37631915
http://dx.doi.org/10.3390/vaccines11081347
_version_ 1785097105052794880
author Chattopadhyay, Anirudha
Jailani, A. Abdul Kader
Mandal, Bikash
author_facet Chattopadhyay, Anirudha
Jailani, A. Abdul Kader
Mandal, Bikash
author_sort Chattopadhyay, Anirudha
collection PubMed
description After two years since the declaration of COVID-19 as a pandemic by the World Health Organization (WHO), more than six million deaths have occurred due to SARS-CoV-2, leading to an unprecedented disruption of the global economy. Fortunately, within a year, a wide range of vaccines, including pathogen-based inactivated and live-attenuated vaccines, replicating and non-replicating vector-based vaccines, nucleic acid (DNA and mRNA)-based vaccines, and protein-based subunit and virus-like particle (VLP)-based vaccines, have been developed to mitigate the severe impacts of the COVID-19 pandemic. These vaccines have proven highly effective in reducing the severity of illness and preventing deaths. However, the availability and supply of COVID-19 vaccines have become an issue due to the prioritization of vaccine distribution in most countries. Additionally, as the virus continues to mutate and spread, questions have arisen regarding the effectiveness of vaccines against new strains of SARS-CoV-2 that can evade host immunity. The urgent need for booster doses to enhance immunity has been recognized. The scarcity of “safe and effective” vaccines has exacerbated global inequalities in terms of vaccine coverage. The development of COVID-19 vaccines has fallen short of the expectations set forth in 2020 and 2021. Furthermore, the equitable distribution of vaccines at the global and national levels remains a challenge, particularly in developing countries. In such circumstances, the exigency of plant virus-based vaccines has become apparent as a means to overcome supply shortages through fast manufacturing processes and to enable quick and convenient distribution to millions of people without the reliance on a cold chain system. Moreover, plant virus-based vaccines have demonstrated both safety and efficacy in eliciting robust cellular immunogenicity against COVID-19 pathogens. This review aims to shed light on the advantages and disadvantages of different types of vaccines developed against SARS-CoV-2 and provide an update on the current status of plant-based vaccines in the fight against the COVID-19 pandemic.
format Online
Article
Text
id pubmed-10458178
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104581782023-08-27 Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness Chattopadhyay, Anirudha Jailani, A. Abdul Kader Mandal, Bikash Vaccines (Basel) Review After two years since the declaration of COVID-19 as a pandemic by the World Health Organization (WHO), more than six million deaths have occurred due to SARS-CoV-2, leading to an unprecedented disruption of the global economy. Fortunately, within a year, a wide range of vaccines, including pathogen-based inactivated and live-attenuated vaccines, replicating and non-replicating vector-based vaccines, nucleic acid (DNA and mRNA)-based vaccines, and protein-based subunit and virus-like particle (VLP)-based vaccines, have been developed to mitigate the severe impacts of the COVID-19 pandemic. These vaccines have proven highly effective in reducing the severity of illness and preventing deaths. However, the availability and supply of COVID-19 vaccines have become an issue due to the prioritization of vaccine distribution in most countries. Additionally, as the virus continues to mutate and spread, questions have arisen regarding the effectiveness of vaccines against new strains of SARS-CoV-2 that can evade host immunity. The urgent need for booster doses to enhance immunity has been recognized. The scarcity of “safe and effective” vaccines has exacerbated global inequalities in terms of vaccine coverage. The development of COVID-19 vaccines has fallen short of the expectations set forth in 2020 and 2021. Furthermore, the equitable distribution of vaccines at the global and national levels remains a challenge, particularly in developing countries. In such circumstances, the exigency of plant virus-based vaccines has become apparent as a means to overcome supply shortages through fast manufacturing processes and to enable quick and convenient distribution to millions of people without the reliance on a cold chain system. Moreover, plant virus-based vaccines have demonstrated both safety and efficacy in eliciting robust cellular immunogenicity against COVID-19 pathogens. This review aims to shed light on the advantages and disadvantages of different types of vaccines developed against SARS-CoV-2 and provide an update on the current status of plant-based vaccines in the fight against the COVID-19 pandemic. MDPI 2023-08-09 /pmc/articles/PMC10458178/ /pubmed/37631915 http://dx.doi.org/10.3390/vaccines11081347 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chattopadhyay, Anirudha
Jailani, A. Abdul Kader
Mandal, Bikash
Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness
title Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness
title_full Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness
title_fullStr Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness
title_full_unstemmed Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness
title_short Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness
title_sort exigency of plant-based vaccine against covid-19 emergence as pandemic preparedness
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458178/
https://www.ncbi.nlm.nih.gov/pubmed/37631915
http://dx.doi.org/10.3390/vaccines11081347
work_keys_str_mv AT chattopadhyayanirudha exigencyofplantbasedvaccineagainstcovid19emergenceaspandemicpreparedness
AT jailaniaabdulkader exigencyofplantbasedvaccineagainstcovid19emergenceaspandemicpreparedness
AT mandalbikash exigencyofplantbasedvaccineagainstcovid19emergenceaspandemicpreparedness